• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 228

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

PT250 – Matt Ball – New Frameworks For Schizophrenia, Dissociation, and...

Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and...

COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in...

Lobe Sciences Appoints Charles Grob, MD to Scientific Advisory Board

Awakn Life Sciences Files Patent Applications In U.S. For AWKN001 And...

MindMed Included in FTSE Russell 3000® Index

Psychedelic Bulletin: Ex-FDA Psychiatry Director Joins Cybin as Advisor; Texas Approves...

Psychedelic Treatment for Eating Disorder Recovery

PTSF65 – Navigating Psychedelics for Clinicians and Therapists, and Nitrous Oxide...

UK Set to Become Hub of Psychedelic Research, as British Startup...

1...227228229...291Page 228 of 291

EDITOR PICKS

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©